Kineta Announces Research Collaboration and License Agreement with Pfizer

Torreya advised Kineta on the transaction

Seattle, WA, December 17, 2018

Kineta Immuno-Oncology, LLC, a subsidiary of Kineta, Inc., announced that it has entered into a strategic research collaboration and license agreement with Pfizer (NYSE: PFE) to develop RIG-I agonist immunotherapies for the treatment of cancer. Under the terms of the agreement, Kineta will receive a $15 million upfront payment and will be eligible to receive up to $505 million in potential research, development and sales milestone payments. Kineta is also eligible to receive tiered royalty on net sales.

The collaboration enables Kineta and Pfizer to leverage each company’s expertise to accelerate the development of the RIG-I immuno-oncology program. In pre-clinical models, Kineta’s RIG-I agonists have demonstrated complete tumor regression and an increase in tumor-specific T cells when given as a monotherapy as well as synergistic effects when used in combination with other immunotherapies like checkpoint inhibitors.

Torreya served as exclusive financial advisor to Kineta on this transaction. This transaction reinforces Torreya’s strength and leadership position as an advisor to biotechnology companies. Torreya has advised on 30 strategic and financing assignments in the life sciences industry thus far in 2018.

ABOUT KINETA, INC.
For more information about Kineta, please see: www.kinetabio.com

Deal Press Release

TORREYA CONTACT

Mark Simon
Partner | New York
mark.simon@torreya.com | 212.257.5809 | torreya.com

Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.